Uterine Fibroids are the abnormal growth that gets developed inside or on the wall of a woman’s uterus. These are also known as leiomyoma or myomas. These are noncancerous growths that cause symptoms such as heavy bleeding between or during the menstrual cycle, pain in pelvis or lower back, increased menstrual cramping, swelling enlargement of the abdomen. Increasing prevalence due to heredity and rising number of treatments to cure this disease has fuelled the growth of this market.
U.S. Uterine Fibroid Market has been segmented on the basis of type which comprises of Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and others. On the basis of diagnosis the market is segmented into Medical Resonance Imaging (MRI) scanners, Computed tomography (CT), Ultrasounds and others. On the basis of treatment the market is segmented into Uterine Fibroid Embolization, Magnetic Resonance Guided Focused Ultrasound, Myolysis, Endometrial Ablation, Hysterectomy and Myomectomy.
The U.S. Market for Uterine Fibroids is expected to reach USD 39,993.2 million by the end of the forecasted period and is expected to grow at a CAGR of 3.24%.
Some of the key players in this market are: AstraZeneca (England), Cook Medical Inc. (US), Boston Scientific Corporation (US), GE Healthcare (U.K.), AbbVie Inc. (U.S.), Hologic (U.S.), and others.
Ø To provide insights about factors, influencing and affecting the market growth.
Ø To provide historically and forecast revenue of the market segments and sub-segments with respect to regional markets and their countries.
Ø To provide historical and forecast revenue of the market segments based on types, diagnosis, and treatment.
Ø To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market.
• Uterine Fibroid Devices and Drug Manufacturers
• Uterine Fibroid Devices and Drug Suppliers
• Private Research Laboratories
• Research and Development (R&D) Companies
• Market Research and Consulting Service Providers
• Medical Research Laboratories
• The U.S. Uterine Fibroid market and is expected to reach USD 39,993.2 million by 2022.
• By Type, Intramural Fibroids holds the largest market share of U.S. uterine fibroid market and is expected to reach USD 14,972.5 million by 2022.
• By Treatment, hysterectomy holds the largest market share of U.S. uterine fibroid market and is expected to reach USD 8,042.3 million by 2022.
The reports also cover country level analysis:
• North America
• Rest of Western Europe
• Eastern Europe
• South Korea
• Rest of Asia
Middle East & Africa
1.1.1 Prevalence of the Uterine Fibroids in U.S.
2 Scope of Study
2.1 Research Objective
2.2 Assumptions & Limitations
2.3 Market Structure
3 Research Methodology
3.1 Primary Research
3.2 Secondary Research
4 U.S. Uterine Fibroid Market
4.2 U.S. Uterine Fibroid Market, By Type
4.3 U.S. Uterine Fibroid Market, By Diagnosis
4.4 U.S. Uterine Fibroid Market, By Treatment
5 Company Profile
5.1.1 Company Overview
5.1.2 Product overview
5.1.3 Financial Overview
5.1.4 Key Development
5.1.5 SWOT Analysis
5.2 Cook Medical Inc.
5.2.2 Product Overview
5.2.4 Key Developments
5.2.5 SWOT Analysis
5.3 Boston Scientific Corporation
5.3.1 Company Overview
5.3.2 Product/Business Segment Overview
5.3.3 Financial Overview
5.3.4 Key Development
5.3.1 SWOT Analysis
5.4 GE Healthcare
5.4.1 Company Overview
5.4.2 Product/Business Segment Overview
5.4.3 Financial Overview
5.4.4 Key Development
5.4.5 SWOT Analysis
5.5 AbbVie Inc.
5.5.1 Company Overview
5.5.2 Product/Business Segment Overview
5.5.3 Financial Overview
5.5.4 Key Development
5.5.5 SWOT Analysis
5.6 Hologic, Inc.
5.6.1 Company Overview
5.6.2 Product/Business Segment Overview
5.6.3 Financial Overview
5.6.4 Key Development
5.6.5 SWOT Analysis